Compare Sanofi India with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs CADILA HEALTHCARE - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA CADILA HEALTHCARE SANOFI INDIA/
CADILA HEALTHCARE
 
P/E (TTM) x 41.0 29.7 138.4% View Chart
P/BV x 8.4 5.2 160.7% View Chart
Dividend Yield % 1.0 0.7 157.1%  

Financials

 SANOFI INDIA   CADILA HEALTHCARE
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
CADILA HEALTHCARE
Mar-20
SANOFI INDIA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs6,840352 1,941.6%   
Low Rs4,630207 2,242.1%   
Sales per share (Unadj.) Rs1,203.1139.2 864.2%  
Earnings per share (Unadj.) Rs165.311.8 1,404.7%  
Cash flow per share (Unadj.) Rs209.918.6 1,130.2%  
Dividends per share (Unadj.) Rs84.003.50 2,400.0%  
Dividend yield (eoy) %1.51.3 116.9%  
Book value per share (Unadj.) Rs963.6101.4 950.8%  
Shares outstanding (eoy) m23.031,023.74 2.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.82.0 237.5%   
Avg P/E ratio x34.723.7 146.1%  
P/CF ratio (eoy) x27.315.0 181.6%  
Price / Book Value ratio x6.02.8 215.9%  
Dividend payout %50.829.8 170.9%   
Avg Mkt Cap Rs m132,078286,033 46.2%   
No. of employees `0003.313.4 24.6%   
Total wages/salary Rs m4,06824,145 16.8%   
Avg. sales/employee Rs Th8,393.810,632.7 78.9%   
Avg. wages/employee Rs Th1,232.41,801.2 68.4%   
Avg. net profit/employee Rs Th1,153.0898.5 128.3%   
INCOME DATA
Net Sales Rs m27,708142,531 19.4%  
Other income Rs m8971,139 78.8%   
Total revenues Rs m28,605143,670 19.9%   
Gross profit Rs m6,23524,198 25.8%  
Depreciation Rs m1,0276,965 14.7%   
Interest Rs m73,418 0.2%   
Profit before tax Rs m6,09814,954 40.8%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2923,198 71.7%   
Profit after tax Rs m3,80612,044 31.6%  
Gross profit margin %22.517.0 132.5%  
Effective tax rate %37.621.4 175.8%   
Net profit margin %13.78.5 162.6%  
BALANCE SHEET DATA
Current assets Rs m15,92287,154 18.3%   
Current liabilities Rs m6,23582,694 7.5%   
Net working cap to sales %35.03.1 1,117.3%  
Current ratio x2.61.1 242.3%  
Inventory Days Days6471 89.1%  
Debtors Days Days2194 22.2%  
Net fixed assets Rs m7,539133,236 5.7%   
Share capital Rs m2301,024 22.5%   
"Free" reserves Rs m21,962102,733 21.4%   
Net worth Rs m22,192103,757 21.4%   
Long term debt Rs m032,146 0.0%   
Total assets Rs m29,839236,866 12.6%  
Interest coverage x872.15.4 16,225.7%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.90.6 154.3%   
Return on assets %12.86.5 195.8%  
Return on equity %17.211.6 147.7%  
Return on capital %27.513.7 200.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58752,752 14.4%   
Fx outflow Rs m7,14514,504 49.3%   
Net fx Rs m44238,248 1.2%   
CASH FLOW
From Operations Rs m3,73925,054 14.9%  
From Investments Rs m-731-10,123 7.2%  
From Financial Activity Rs m-1,972-10,942 18.0%  
Net Cashflow Rs m1,0363,989 26.0%  

Share Holding

Indian Promoters % 0.0 74.8 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 8.3 173.5%  
FIIs % 14.6 5.9 247.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 11.0 95.5%  
Shareholders   15,184 44,069 34.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   FDC  UNICHEM LAB  PROCTER & GAMBLE HEALTH  AJANTA PHARMA  ALEMBIC  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Apr 16, 2021 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS